ArticlePediatric research2026
Immunoglobulin A concentration is lower in mothers' own milk and infant stool in infants who develop necrotising enterocolitis.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunoglobulin A (IgA) binding gut bacteria may modulate necrotising enterocolitis (NEC). In infants <32 weeks gestation exclusively receiving their mother's own milk (MOM) who either did or did not develop NEC, we explored IgA concentration in MOM and infant stool.
methodsWe quantified IgA and secretory IgA (sIgA) concentration by enzyme linked immunosorbent assay (ELISA). 41 NEC (median onset day 22) and 44 matched control infants, median gestation 25 weeks, contributed 202 MOM and 92 stool samples.
resultsIgA and sIgA in MOM were significantly lower for the first three weeks in infants developing NEC compared to control infants (median IgA 499 μg/ml vs 1261 µg/ml, sIgA 481 µg/ml versus 1023 µg/ml, adjusted p < 0.001 between 0-6 and 7-13 days of life, adjusted p = 0.029 days 14-20). Stool IgA concentration before disease was also significantly lower in NEC infants compared with control infants (262 µg/ml versus 491 µg/ml, p = 0.045), but there was no statistical difference in sIgA.
conclusionIgA and sIgA are lower in early MOM (before week 3 of life) received by infants who go on to develop NEC, reflected in lower stool IgA. Potential mechanisms require further elucidation. Targeted use of high IgA donor milk to preterm infants may be beneficial. IMPACT: This is the first published work that evaluates both milk and stool IgA and sIgA in control preterm infants and those developing NEC and has the benefit of samples taken before disease onset for some infants. In this study, IgA and sIgA are lower in early MOM (before week 3 of life) received by infants who go on to develop NEC, reflected in lower stool IgA. Targeted use of high IgA donor milk to preterm infants may be beneficial. Clinical practice in the interim should focus on maximising fresh MOM delivery to preterm babies.
Indexed as
Identifiers
41339769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.